<DOC>
	<DOC>NCT00725296</DOC>
	<brief_summary>This is a prospective, open-label, 1-arm, multicenter observational study to determine the dose and time interval of Remicade (Infliximab) infusions in psoriatic arthritis (PsA).</brief_summary>
	<brief_title>Investigation of 9 Consecutive Infusions of Remicade for Psoriatic Arthritis in Austria (Study P04264)</brief_title>
	<detailed_description>This study population was chosen from a non-probability sample.</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Participants with active and progressive psoriatic arthritis who have responded inadequately to diseasemodifying antirheumatic drugs. All according to contraindications in the label especially: Participants with tuberculosis or other severe infections such as sepsis, abscesses, and opportunistic infections. Participants with moderate or severe heart failure (NYHA class III/IV). Participants with a history of hypersensitivity to infliximab or to other murine proteins, or to any of the excipients.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>